Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline UpdateCharles L. Loprinzi, Dawn L. Hershman, Christina Lacchetti et al.|Journal of Clinical Oncology|2020Cited by 1.1k
Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overviewAlexandre Chan, Maryam B. Lustberg, Samantha Mayo et al.|Supportive Care in Cancer|2019Cited by 79
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)Daniel L. Hertz, Maryam B. Lustberg, Daniel S. Childs et al.|Cancer Treatment Reviews|2021Cited by 63
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyDaniel L. Hertz, Howard L. McLeod, Kouros Owzar et al.|Clinical Cancer Research|2016Cited by 57
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N. Patel, Howard L. McLeod, Chen Jiang et al.|Cancer|2014Cited by 35